They're the most-hyped "growth hormone" peptide stack in the anti-aging world — and two of the most over-promised. Here's what ipamorelin and CJC-1295 actually are, what the science does and doesn't show, and exactly where they stand with the FDA in 2026.
Ipamorelin and CJC-1295 are growth-hormone secretagogues — peptides that signal the pituitary gland to release the body's own growth hormone, rather than supplying the hormone directly. They're almost always discussed together as a stack, because they work through two different doors:
The honest headline: most of the human evidence is thin. These are popular in anti-aging and fitness circles, but rigorous human clinical trials for those uses are very limited, so claims that the stack reliably builds muscle, burns fat, or "reverses aging" run well ahead of the data. That gap between loud marketing and thin human evidence is exactly what this page exists to close.
Neither is an FDA-approved drug, and the regulatory picture has tightened:
Want the live picture? Our regulatory-status tracker shows exactly where ipamorelin, CJC-1295, and other peptides stand right now, with the dated primary sources.
The mechanism is well characterized: in studies, CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist) each raise growth-hormone release, and combining them produces both a sustained and an acute GH pulse. Ipamorelin in particular is noted for being selective — raising GH without meaningfully spiking cortisol in the studies that defined it.
The popular anti-aging, muscle-gain, fat-loss, and recovery claims are a different story. Controlled human trials supporting those outcomes are scarce, and much of what circulates online is anecdote, not data. That doesn't mean the peptides "do nothing" to GH levels — it means the evidence needed to say the stack delivers those real-world benefits, safely, in healthy people, largely isn't there yet. Treat confident before-and-after claims with skepticism.
Because neither peptide is FDA-approved, there is no official dosing. Commonly reported subcutaneous doses sit around 0.2–0.3 mg ipamorelin (200–300 mcg) combined with ~0.1 mg CJC-1295 (100 mcg), often once or twice daily as a stack. To be clear: these are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice. Any decision belongs with a licensed provider.
These peptides typically ship as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before they're a liquid. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal in micrograms is a 1,000× error. That's what our free tool is for:
Commonly reported effects are mild and local — for example, irritation or redness at the injection site — alongside occasional flushing, headache, water retention, or a brief head-rush after injection. Because these peptides raise growth-hormone signaling, the broader cautions that apply to growth-hormone elevation are worth weighing with a provider. Long-term safety in humans is simply not well established, and product quality varies enormously between sources. Because much of the supply is research-use-only and unregulated, purity, sterility, and accurate labeling are real concerns — which is why sourcing and testing matter as much as the molecules themselves.
If you're considering this stack, the responsible path runs through a licensed provider who can weigh your situation, not a checkout page. Questions worth asking: Is there third-party testing and a certificate of analysis? What's the source and is it disclosed? Is this research-use-only material? What does the provider make of the current legal status, given there's no compounding pathway? This isn't legal or medical advice — it's the baseline diligence any unapproved substance deserves.
No. HGH (human growth hormone) is the hormone itself. Ipamorelin and CJC-1295 are secretagogues that prompt your own pituitary to release growth hormone — they work upstream rather than supplying the hormone directly.
DAC (drug affinity complex) dramatically extends the half-life, allowing far less frequent dosing; the no-DAC version is shorter-acting and often dosed more often. Both are unapproved. We describe this for context only, not as a dosing recommendation.
Growth-hormone secretagogues are on the World Anti-Doping Agency (WADA) prohibited list, and neither peptide is FDA-approved. "Banned" depends on context — competition, prescription, and import rules all differ. Verify for your situation.
We don't sell peptides and we don't direct consumers to buy unapproved substances. If a licensed provider determines it's appropriate, sourcing and testing should be part of that conversation.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.